Skip to main content
Top
  • FDA MedWatch: Recall - Brilinta (ticagrelor) 90 mb tablets, 8-count Physician Sample Bottles

    Friday, May 26, 2017

    AstraZeneca is notifying physicians and consumers that it is voluntarily recalling one lot of professional (physician) sample bottles containing eight tablets of Brilinta (ticagrelor) 90mg tablets as a precautionary measure. This voluntary recall follows a report that a professional sample bottle containing eight tablets of Brilinta 90mg also contained another medicine called Zurampic (lesinurad) 200 mg tablets which is also manufactured by AstraZeneca.

    Read More
  • New CDC Report: Spread of Resistant Fungus, C. auris

    Thursday, May 25, 2017

    CDC has just released an MMWR update on Candida auris (C. auris) cases identified in U.S. health care facilities through May 2017. In June 2016, CDC released the first clinical alert about C. auris. Soon after, CDC began reporting on the first U.S. cases. Although C. auris is still rare in the United States, we are seeing an increasing number of cases. The MMWR provides information on the 77 C. auris cases reported to CDC through May 12, 2017.

    Read More
  • FDA MedWatch: Canagliflozin (Invokana, Invokamet): Drug Safety Communication - Increased Risk of Leg and Foot Amputations

    Tuesday, May 16, 2017

    Based on new data from two large clinical trials, the FDA has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. FDA is requiring new warnings, including the most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk.

    Read More
  • CDC Health Advisory: Prolonged IgM Antibody Resopnse in People Infected with Zika Virus

    Monday, May 8, 2017

    In July 2016, CDC issued Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure – United States, July 2016 (https://www.cdc.gov/mmwr/volumes/65/wr/mm6529e1.htm) that includes Zika virus immunoglobulin M (IgM) testing of pregnant women. However, some flavivirus infections can result in prolonged IgM responses (>12 weeks) that make it difficult to determine the timing of infection, especially in testing of asymptomatic people.

    Read More